BioArctic AB (publ) (BRCTF)
USD 15.67
(0.0%)
USD 15.67
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 229.24 Million SEK | 2150.71% |
| 2022 | -11.17 Million SEK | 90.67% |
| 2021 | -119.78 Million SEK | -74.83% |
| 2020 | -68.51 Million SEK | -177.45% |
| 2019 | 88.46 Million SEK | -76.82% |
| 2018 | 381.6 Million SEK | 2417.66% |
| 2017 | 15.15 Million SEK | -73.68% |
| 2016 | 57.58 Million SEK | 1452.02% |
| 2015 | 3.71 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -68.42 Million SEK | -18.87% |
| 2024 Q1 | -57.56 Million SEK | 34.02% |
| 2023 Q3 | 124.95 Million SEK | 222.12% |
| 2023 Q4 | -87.24 Million SEK | -169.82% |
| 2023 Q2 | -102.31 Million SEK | -134.82% |
| 2023 Q1 | 293.85 Million SEK | 607.72% |
| 2023 FY | 229.24 Million SEK | 2150.71% |
| 2022 Q3 | 136.79 Million SEK | 398.43% |
| 2022 FY | -11.17 Million SEK | 90.67% |
| 2022 Q4 | -57.87 Million SEK | -142.31% |
| 2022 Q2 | -45.83 Million SEK | -3.57% |
| 2022 Q1 | -44.25 Million SEK | -133.48% |
| 2021 FY | -119.78 Million SEK | -74.83% |
| 2021 Q2 | -34.17 Million SEK | -17.5% |
| 2021 Q3 | -37.57 Million SEK | -9.93% |
| 2021 Q4 | -18.95 Million SEK | 49.55% |
| 2021 Q1 | -29.08 Million SEK | -120.38% |
| 2020 Q1 | 3.55 Million SEK | 120.79% |
| 2020 Q4 | -13.19 Million SEK | 36.09% |
| 2020 Q3 | -20.65 Million SEK | 45.97% |
| 2020 Q2 | -38.22 Million SEK | -1175.46% |
| 2020 FY | -68.51 Million SEK | -177.45% |
| 2019 Q4 | -17.09 Million SEK | -105.21% |
| 2019 Q2 | 100.26 Million SEK | 635.68% |
| 2019 Q1 | 13.62 Million SEK | -95.93% |
| 2019 FY | 88.46 Million SEK | -76.82% |
| 2019 Q3 | -8.33 Million SEK | -108.31% |
| 2018 Q2 | 5.12 Million SEK | -66.79% |
| 2018 FY | 381.6 Million SEK | 2417.66% |
| 2018 Q4 | 335.2 Million SEK | 1196.43% |
| 2018 Q3 | 25.85 Million SEK | 404.9% |
| 2018 Q1 | 15.41 Million SEK | 30.26% |
| 2017 Q1 | 1.11 Million SEK | -98.51% |
| 2017 FY | 15.15 Million SEK | -73.68% |
| 2017 Q2 | 2.32 Million SEK | 107.97% |
| 2017 Q4 | 11.83 Million SEK | 10304.31% |
| 2017 Q3 | -116 Thousand SEK | -105.0% |
| 2016 Q1 | -4.81 Million SEK | 0.0% |
| 2016 FY | 57.58 Million SEK | 1452.02% |
| 2016 Q4 | 74.96 Million SEK | 1066.29% |
| 2016 Q3 | -7.75 Million SEK | 10.75% |
| 2016 Q2 | -8.69 Million SEK | -80.58% |
| 2015 FY | 3.71 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 13370.91% |
| CSL Limited | 2.64 Billion USD | 91.323% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 405.816% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 3586.088% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 83950.52% |
| Evofem Biosciences, Inc. | 52.97 Million USD | -332.717% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | -251.971% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 12692.446% |
| Mesoblast Limited | -87.95 Million USD | 360.641% |
| Marizyme, Inc. | -65.34 Million USD | 450.818% |
| Genus plc | 7.9 Million USD | -2801.886% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 2204.797% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 6278.829% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 2692.142% |
| ContraFect Corporation | -65.15 Million USD | 451.863% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 4791.896% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| IMV Inc. | -36.48 Million USD | 728.326% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 2944.393% |
| MultiCell Technologies, Inc. | -380.07 USD | 60317673.079% |
| Accustem Sciences Inc. | -3.74 Million USD | 6219.15% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 543.49% |
| EV Biologics, Inc. | -1.26 Million USD | 18191.93% |
| Q BioMed Inc. | -2.05 Million USD | 11271.472% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 6241.147% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 9728.791% |
| Biomind Labs Inc. | -1.21 Million USD | 18978.812% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 3000.75% |
| Skye Bioscience, Inc. | -37.64 Million USD | 708.979% |
| SQZ Biotechnologies Company | -79.46 Million USD | 388.494% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | 1530875.908% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 3383.036% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 8025.926% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 1544.412% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 36350.231% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | -10.54 Million USD | 2273.388% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 10665.376% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 4040.846% |
| GB Sciences, Inc. | -1.36 Million USD | 16935.784% |
| Alpha Cognition Inc. | -13.77 Million USD | 1764.534% |
| argenx SE | -295.05 Million USD | 177.698% |
| HST Global, Inc. | -146.21 Thousand USD | 156894.337% |
| Halberd Corporation | -79.67 Thousand USD | 287826.542% |
| Enzolytics Inc. | -2.17 Million USD | 10631.313% |
| Resverlogix Corp. | -3.61 Million USD | 6450.388% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 7328.555% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 466.218% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 483.838% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | -233827.551% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 7490.914% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | -3210.649% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 11860.888% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 5870.184% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 7675.637% |
| AVAX Technologies, Inc. | -6.41 Million USD | 3674.393% |
| ONE Bio Corp. | 8.67 Million USD | -2542.149% |
| Zenith Capital Corp. | -10.59 Million USD | 2263.543% |
| Genscript Biotech Corporation | -95.47 Million USD | 340.109% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | 986456.596% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 5629.487% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | 379396.304% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 11533.21% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 13164.326% |
| Agentix Corp. | -1.37 Million USD | 16782.227% |
| Adynxx, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | -3.3 Million USD | 7031.4% |
| Helix BioMedix, Inc. | -1.05 Million USD | 21808.014% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 6102.854% |
| BioStem Technologies, Inc. | -8.48 Million USD | 2802.457% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 52040.44% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 17266.668% |
| LadRx Corporation | 400.44 Thousand USD | -57148.847% |
| Cell Source, Inc. | -5.32 Million USD | 4408.21% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 55277.037% |
| Regen BioPharma, Inc. | 1.02 Million USD | -22298.359% |
| Regen BioPharma, Inc. | 1.02 Million USD | -22298.359% |
| NovAccess Global Inc. | -4.76 Million USD | 4906.878% |
| Affymax, Inc. | -14.42 Million USD | 1689.358% |
| Itoco Inc. | -1.86 Million USD | 12365.897% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 5260.32% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 13835.71% |
| CytoDyn Inc. | -49.84 Million USD | 559.961% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | 290167.44% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 100591.831% |
| Qrons Inc. | -789.34 Thousand USD | 29142.867% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 24448.586% |
| SYBLEU INC | -180.3 Thousand USD | 127245.82% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | 11081.031% |
| Rebus Holdings, Inc. | -1.02 Million USD | 22575.392% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 14314.903% |
| Mobile Lads Corp. | -2.26 Million USD | 10229.007% |
| International Stem Cell Corporation | -131 Thousand USD | 175099.237% |
| Bioxytran, Inc. | -4.28 Million USD | 5456.283% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | 422507.503% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 9160.341% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 576.887% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 10944.324% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 29457.513% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 7336.395% |
| Neutra Corp. | -233.46 Thousand USD | 98294.162% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 1229.806% |
| PureTech Health plc | -65.69 Million USD | 448.949% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 1177.98% |
| IXICO plc | -1.17 Million USD | 19560.866% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 2409.348% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 501.29% |
| CSL Limited | 2.64 Billion USD | 91.323% |
| Cellectis S.A. | -103.17 Million USD | 322.197% |